In models of melanoma and renal cell carcinoma, administration of a high dose IL-2 based immunotherapy correlates with an elevated T regulatory (Treg) cell response associated with down regulation of tumor specific immunity [8]. This evidence concerns the gene IL2 and neoplasm.